Finally, analysis of the “GSE11121” dataset (n = 199 untreated after surgery of LNN breast cancer patients [37] showed that high geminin + HMGB1 expressing patients (n = 100) had significantly shorter metastatic-free survival (MFS) than low expressing patients (n = 99, HR = 3.38, 95% CI = 1.7–6.72, p = 0.0005, Figure 3M). Here, GMNN is linked to breast cancer.